Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding Div RTS (OP:RHHVF)

478.36 -0.30 (-0.06%)
Streaming Delayed Price Updated: 12:06 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding Div RTS

< Previous 1 2 3 4 5 6 7 Next >
News headline image
EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody ↗
The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those... 
Via Benzinga
News headline image
New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients ↗
 
Via Benzinga
News headline image
FDA Casts Doubts Over Roche's Polivy Label Expansion For Untreated Lymphoma Setting ↗
 
Via Benzinga
News headline image
Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo ↗
 
Via Benzinga
News headline image
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines ↗
 
Via Benzinga
News headline image
New Data Shows Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder ↗
 
Via Benzinga
News headline image
Roche Touts Positive Crovalimab Data From Late-Stage Study In Rare Blood Condition ↗
 
Via Benzinga
News headline image
Roche Flags Lower 2023 Sales On Declining Demand For COVID-19 Treatment, Diagnostics ↗
 
Via Benzinga
News headline image
Genentech's Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer ↗
 
Via Benzinga
News headline image
Europe Approves Xofluza, Roche's Revolutionary Influenza Antiviral with New Mechanism ↗
 
Via Benzinga
News headline image
Roche's Investigational Lymphoma Candidate Goes Under FDA Priority Review ↗
 
Via Benzinga
News headline image
Roche's Follicular Lymphoma Therapy Scores FDA Approval ↗
 
Via Benzinga
News headline image
FDA Approves Roche's Tocilizumab As First Monoclonal Antibody For COVID-19 Treatment ↗
 
Via Benzinga
News headline image
Roche Presents New Data Demonstrating Potential Benefit Of Two Lymphoma Candidates ↗
 
Via Benzinga
News headline image
After 16 Years, Roche's Pharma Division Head Decides To Step Down ↗
 
Via Benzinga
News headline image
Replimune Shares Surge After Early Data From Pretreated Melanoma Patients ↗
 
Via Benzinga
News headline image
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says ↗
 
Via Benzinga
News headline image
FDA Gives Emergency Use Nod To Roche's Monkeypox Test ↗
 
Via Benzinga
News headline image
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage ↗
 
Via Benzinga
News headline image
Roche Inks Second Drug Discovery Deal With Jnana Therapeutics ↗
 
Via Benzinga
News headline image
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers ↗
 
Via Benzinga
News headline image
Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months ↗
 
Via Benzinga
News headline image
Roche Posts Lower Quarterly Sales As Demand For COVID Products Slide ↗
 
Via Benzinga
News headline image
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients ↗
 
Via Benzinga
News headline image
Roche To Introduce Next-Generation Portfolio Of COVID-19 Rapid Tests ↗
 
Via Benzinga
News headline image
EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility ↗
Lineage Cell Therapeutics Inc (NYSE: LCTX) has opened a new research and development facility in Carlsbad, California. 
Via Benzinga
News headline image
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests ↗
 
Via Benzinga
News headline image
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns ↗
The World Health Organization (WHO) warned that it struggles to identify and 
Via Benzinga
News headline image
Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders ↗
 
Via Benzinga
News headline image
WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete ↗
Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.